Drug Discovery for Parkinson's With Mutations in the GBA Gene

Launched by NEW YORK STEM CELL FOUNDATION RESEARCH INSTITUTE · Sep 7, 2022

Keywords

ClinConnect Summary

The clinical trial titled "Drug Discovery for Parkinson's With Mutations in the GBA Gene" is being conducted by the New York Stem Cell Foundation (NYSCF) Research Institute. The main goal of this research is to find new treatments or even cures for Parkinson's disease by using cells taken from participants. These can be skin or blood cells, which the researchers will turn into stem cells to study and test. By understanding how Parkinson's disease affects people, especially those with a specific mutation in the GBA gene, the team hopes to speed up the development of potential therapies.

To participate in this trial, you need to be at least 18 years old and have a diagnosis of Parkinson's disease, Gaucher disease, or be a healthy control. Participants will need to give written consent to join the study, but if someone has trouble signing, they may be allowed to participate without it. It's important to know that certain health conditions may prevent someone from joining, such as issues with blood clotting or previous reactions to anesthesia. If you choose to participate, you can expect to provide samples of your cells for research, which will be handled safely and ethically. This study is currently looking for participants, so if you meet the criteria and are interested, you may have the chance to contribute to important research in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older.
• • Diagnosis of Parkinson's disease, Gaucher disease, or healthy control.
• • Must provide written informed consent unless physical limitations preclude signing.
• Exclusion Criteria:
• • For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.
• • For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection.
• • For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.